Traders should monitor the outcome of the April 16 FDA meeting for guidance on trial design and potential approval pathway, which could serve as a near-term catalyst. Positive alignment with the FDA may support valuation upside in this niche oncology space.
Price Chart
Executive Summary
Oncolytics Biotech announced a scheduled Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in combination with a checkpoint inhibitor for squamous cell anal carcinoma (SCAC). The company plans to propose a single-arm pivotal study enrolling 60–70 patients with objective response rate as the primary endpoint, supported by clinical data showing approximately 30% ORR and 17-month median duration of response.
Key Facts
- Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in SCAC.
- The proposed pivotal study is single-arm, enrolling 60–70 patients, with objective response rate (ORR) as the primary endpoint.
- Clinical data from Cohort 4 of the GOBLET study showed approximately 30% ORR and 17-month median duration of response in late-line SCAC patients.
- SCAC is a rare cancer with limited second-line treatment options, positioning pelareorep for a potentially efficient approval path.
- The FDA has previously granted Fast Track designation to pelareorep for colorectal and pancreatic cancers.
Financial Impact
No immediate financial impact disclosed; potential long-term value hinges on FDA agreement and study initiation.
Risk Factors
- FDA may not agree to the proposed single-arm pivotal study design or endpoint.
- Limited patient population and rare cancer indication may constrain commercial revenue potential despite approval.
- Company remains dependent on future financing or partnerships to fund pivotal development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000024 |
| Document: oncolyticsfdascacmeetingpr.htm | 0001129928-26-000024 |
| Document: 0001129928-26-000024-index-headers.html | 0001129928-26-000024 |
| Document: 0001129928-26-000024-index.html | 0001129928-26-000024 |
| Document: 0001129928-26-000024.txt | 0001129928-26-000024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access